Belviq, a weight loss medication containing the active ingredient lorcaserin, carries a documented cancer risk that led to its withdrawal from the U.S. market in 2020. After the FDA requested withdrawal on January 14, 2020, following evidence of increased cancer diagnoses in clinical trials, manufacturer Eisai Inc. pulled the drug and its extended-release version, Belviq XR, from shelves by February 2020. Since then, thousands of patients who took the drug have pursued class action litigation to recover damages for cancer diagnoses they believe are linked to their use of the medication.
The cancer risk associated with Belviq emerged from a landmark clinical trial tracking 12,000 patients over five years. Researchers found that 7.7% of Belviq users developed cancer compared to 7.1% of those taking a placebo—a seemingly small difference that translates to hundreds of additional cancer cases among the millions of Americans who took the drug. Pancreatic, colorectal, and lung cancers were most frequently associated with Belviq use, and the risk increased the longer patients remained on the medication, suggesting a dose-response relationship that raised serious safety concerns. Those affected by Belviq-related cancer diagnoses now face a complex landscape of pending lawsuits and settlement negotiations. While Eisai reached a $125 million settlement in April 2021 to resolve early claims, the broader litigation remains in flux, with settlement negotiations spanning multiple years and no jury trials currently scheduled.
Table of Contents
- What Evidence Showed Belviq Increased Cancer Risk?
- The Timeline of Belviq’s Approval, Problems, and Market Withdrawal
- How Many People Filed Belviq Cancer Lawsuits?
- Understanding the Settlement Process for Belviq Cancer Claims
- What Limitations and Challenges Remain in Belviq Litigation?
- Which Cancer Types Are Most Commonly Linked to Belviq?
- What Does the Future Hold for Belviq Litigation and Settlement?
- Conclusion
What Evidence Showed Belviq Increased Cancer Risk?
The evidence against Belviq came from a rigorous five-year clinical trial designed to assess the drug’s cardiovascular safety and efficacy. Eisai and Arena Pharmaceuticals, the Switzerland-based manufacturer of lorcaserin, enrolled 12,000 patients in this study to monitor long-term outcomes. The trial revealed a consistent pattern: cancer occurred in 7.7% of patients taking Belviq compared to 7.1% taking placebo. While the absolute difference appears modest, the trial was large enough to detect that this represented a statistically significant increase in cancer risk. The specific cancer types linked to Belviq use included pancreatic cancer, colorectal cancer, and lung cancer—three aggressive malignancies with poor prognosis rates.
What made the data particularly troubling was the dose-response relationship: patients who took Belviq for longer periods faced higher cumulative cancer risk. This pattern strongly suggested that the drug itself, rather than coincidental factors or pre-existing conditions, was driving the increased cancer incidence. For example, a patient who took Belviq for three years faced greater cancer risk than someone who took it for six months, indicating that continued exposure to lorcaserin compounded the threat. The FDA’s response was swift and decisive. The agency requested that Eisai voluntarily withdraw Belviq from the market, a request the company honored within weeks. This represented a rare reversal of an FDA-approved medication, underscoring the severity of the safety signal detected in the clinical trial data.
The Timeline of Belviq’s Approval, Problems, and Market Withdrawal
Belviq initially received FDA approval as an obesity treatment before the full scope of its cancer risk became apparent. The drug was marketed to millions of Americans seeking weight loss solutions, with doctors prescribed it based on the understanding that the medication was safe when used as directed. For several years, Belviq remained on pharmacy shelves and in medicine cabinets across the country, with no public warnings about cancer risk. The clinical trial that exposed the problem continued collecting data even after Belviq hit the market. As the five-year follow-up period concluded and researchers analyzed the complete dataset, the cancer signal became unmistakable. On January 14, 2020, the FDA formally requested withdrawal.
A critical limitation of this timeline is that patients who had already taken Belviq for extended periods had no way to undo their exposure; they faced years of uncertainty about whether they would develop cancer. Some patients learned they had cancer only after the withdrawal announcement forced them to retrospectively connect their diagnosis to their medication use. By February 2020, Eisai had complied fully, removing all Belviq and Belviq XR from the U.S. market. However, the withdrawal did nothing to address the cancer risk already created in patients who had taken the drug. This lag between when the drug was in circulation and when the danger became undeniable is a key driver of the subsequent class action litigation.
How Many People Filed Belviq Cancer Lawsuits?
Thousands of individuals who developed cancer after taking Belviq initiated legal claims, seeking compensation from Eisai and Arena. The volume of cases was substantial enough that class action litigation was pursued, though notably, the U.S. Judicial Panel on Multidistrict Litigation denied requests to consolidate the claims into a single centralized proceeding. Consolidation is typically granted when there are hundreds or thousands of similar cases, but the panel determined that the Belviq litigation did not meet the threshold for centralization, leaving cases scattered across multiple federal courts. This fragmented litigation landscape created both opportunities and challenges for plaintiffs.
On one hand, lawsuits proceeded in various venues, giving plaintiffs options for where their cases would be heard. On the other hand, the lack of a unified MDL meant there was no single coordinating judge, no standardized discovery process, and less leverage for negotiating a comprehensive global settlement. Each plaintiff essentially had to navigate their claim through the specific federal court in their jurisdiction. Despite the decentralized structure, settlement activity has proceeded steadily. The April 2021 settlement of $125 million represented a major breakthrough, providing compensation to early claimants without requiring them to prove their specific case at trial. Eisai’s willingness to settle suggested the company anticipated significant litigation costs and unfavorable jury verdicts if cases proceeded to trial.
Understanding the Settlement Process for Belviq Cancer Claims
For patients who took Belviq and later developed cancer, the settlement process offered an alternative to pursuing a jury trial. Rather than waiting years for trial, potentially facing legal costs, and risking an unfavorable verdict, eligible claimants could submit a claim to the settlement fund and receive compensation based on predetermined amounts. The $125 million settlement reached in April 2021 was the first major resolution, though ongoing negotiation for a global settlement continued through 2022 and into 2023. In May 2022, a significant development occurred: a U.S. district judge paused all pending Belviq cases to allow Eisai and Arena to pursue comprehensive settlement negotiations.
This litigation hold lasted months, with the court recognizing that settling all claims globally would be preferable to endless individual litigation. By February 2023, a confidential settlement was reached with at least one Florida plaintiff who had developed breast cancer after using Belviq, signaling that settlement discussions were continuing and producing results. The comparison here is instructive: whereas a plaintiff might have waited three to five years for a jury trial, with uncertain outcomes, the settlement process compressed the timeline to months and provided guaranteed compensation. However, a notable trade-off exists. In exchange for receiving settlement funds relatively quickly, most claimants must agree to release Eisai and Arena from further liability and typically must keep settlement details confidential. This means no public determination of fault, no jury verdict establishing causation, and limited transparency about how much individual claimants receive compared to others.
What Limitations and Challenges Remain in Belviq Litigation?
One critical limitation of the current litigation landscape is that no trials have been scheduled, meaning no jury has publicly ruled on whether Belviq actually caused any individual’s cancer. Without trial verdicts, the legal question of causation—whether lorcaserin directly caused a patient’s pancreatic, colorectal, or lung cancer—remains unadjudicated. This creates a ceiling on settlement valuations, because Eisai can negotiate settlements without ever admitting that the drug caused cancer or conceding the strength of plaintiffs’ evidence. Another challenge is proving causation at the individual level. The clinical trial showed that 7.7% of Belviq users developed cancer versus 7.1% of placebo recipients, but this population-level data doesn’t automatically prove that any specific individual’s cancer was caused by Belviq.
A patient might have developed cancer for entirely separate reasons: smoking history, genetic predisposition, environmental exposures, or other risk factors. Proving that Belviq, rather than these other factors, caused a specific cancer diagnosis is technically difficult and requires expert testimony, detailed medical records, and often years of litigation. Furthermore, the litigation stayed status since 2022 means that many claims have been in limbo for years without resolution. While settlement negotiations proceed, claimants cannot move their cases forward through normal discovery or trial. For some patients, this delay is frustrating, particularly those with limited life expectancy due to advanced cancer, who may die before their claim is resolved. The warning here is clear: claimants should understand that settlements may take years to finalize, even after withdrawal of the drug and acknowledgment of elevated cancer risk.
Which Cancer Types Are Most Commonly Linked to Belviq?
The clinical trial data identified pancreatic, colorectal, and lung cancer as the malignancies most frequently associated with Belviq use. Pancreatic cancer carries particularly grim prognosis rates—only about 10% of patients survive five years after diagnosis—making any connection to a weight loss drug especially tragic. A patient who took Belviq for weight loss and subsequently developed pancreatic cancer faces not only the trauma of the diagnosis but also the knowledge that the medication intended to improve their health may have directly triggered their cancer.
Colorectal and lung cancers also appeared at elevated rates in the Belviq-treated group, though the mechanism by which lorcaserin might increase these specific cancer risks remains unclear. Some researchers have speculated that the drug might affect cellular proliferation or modify protective immune responses, but the exact biological pathway has not been definitively established. An example involves a patient who took Belviq for two years, then was diagnosed with stage III colorectal cancer at age 52; this person would likely have a strong claim for settlement, as the temporal relationship between drug use and diagnosis aligns with the clinical trial findings.
What Does the Future Hold for Belviq Litigation and Settlement?
As of 2024 and beyond, the Belviq litigation continues to evolve, with global settlement negotiations between Eisai, Arena, and plaintiff representatives ongoing. The rejection of MDL centralization means that litigation will likely continue to proceed through regional federal courts, with settlement being the primary mechanism for resolving claims rather than jury trials. This forward-looking arrangement suggests that the litigation will not produce major jury verdicts or appeals that establish clear legal precedent about Belviq’s causative role in cancer.
The broader implications for pharmaceutical regulation and consumer protection are substantial. Belviq represents a case where an FDA-approved medication was discovered to carry significant cancer risk only years after approval, affecting hundreds of thousands of users. Future oversight may include more rigorous long-term safety monitoring, faster withdrawal procedures when safety signals emerge, and stronger manufacturer accountability for delayed disclosure of cancer risks.
Conclusion
Belviq’s cancer risk represents a serious public health failure: a medication approved by the FDA and prescribed to millions of Americans turned out to increase cancer rates in a large clinical trial. The drug’s swift withdrawal in February 2020, following the FDA’s January 2020 safety request, came too late for the many patients who had already taken lorcaserin and later developed pancreatic, colorectal, or lung cancer. Eisai’s settlement of $125 million in April 2021, combined with ongoing negotiation of a global settlement, demonstrates the significant legal and financial accountability the company has faced.
If you or a family member took Belviq and subsequently developed cancer, you may be eligible for compensation through the ongoing settlements or through individual litigation. The litigation landscape remains fragmented across multiple federal courts, with litigation stayed pending settlement negotiations. To understand your rights, review available settlement claim procedures, gather your medical records documenting both your Belviq use and your cancer diagnosis, and consider consulting with a class action attorney who specializes in pharmaceutical injuries. Time may be limited, as settlement claim periods often have deadlines, and the sooner you act, the sooner you can obtain compensation for the harm caused by this medication.